Table 5. Clinical characteristics of 6 advanced, sporadic biliary tract cancer patients.

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6
Age (years)	64	66	50	62	50	43
Gender	F	M	M	F	F	F
Location of Primary Tumor	Intrahepatic	Intrahepatic/Gallbladder	Intrahepatic	Intrahepatic	Intrahepatic	Intrahepatic
Stage	III	IV	IV	IV	IV	IV
CA19-9 (Units/ml)	WNL	1008	WNL	WNL*	N/A	56
Sites of Metastasis	N/A	Abdominal Lymph Nodes	Cervical,Thoracic, Abdominal, Pelvic Lymph Nodes	Abdominal, Pelvic Lymph Nodes, Liver	Liver, Lungs, Peritoneum	Lungs
Underlying Etiology	Unknown	Unknown	Unknown	Unknown	Unknown	Unknown
Liver fluke	No	No	No	No	No	No
Hepatitis B	Unknown	Unknown	Negative	Unknown	Unknown	Unknown
Hepatitis C	Unknown	Unknown	Negative	Unknown	Unknown	Unknown
Prior Surgical Resection	No	Yes	Yes	No	Yes	No
Prior Radiation Therapy	No	No	No	No	No	No
Systemic Chemotherapy	Gem/Cis	Gem/Cis, Capecitabine	Gem/Cis	Gem/Cis, Gem/Cape, PEGPH20	Gem/Cis, 5-FU/Carbo	Gem/Cis, FOLFOX, Pazopanib
Survival Status	Alive	Dead	Dead	Alive	Dead	Alive
Survival Duration from biopsy (months)	14.5+	8.8	9.0	9.3+	4.1	5.5+

F = female; M = male; WNL = Within Normal Limits; Gem/Cis = Gemcitabine and Cisplatin; Gem/Cape = Gemcitabine and Capecitabine; PEGPH20 = pegylated hyaluronidase; 5-FU/Carbo = 5-Fluorouracil and Carboplatin; FOLFOX – 5-FU, Leucovorin and Oxaliplatin,

^* = WNL at baseline but 1408 U/ml prior to therapy and N/A = Not Available.